Endologix (NSDQ:ELGX) said it won FDA Investigational Device Exemption for its Nellix endovascular aneurysm sealing system, paving the way for a U.S. clinical trial.
Endologix
Endologix offers $75M in convertible notes
Cambridge Heart chairman, ex-CEO both resign | Personnel Moves
Cambridge Heart (NSDQ:CAMH) said chairman and interim president Roderick de Greef and former president & CEO Ali Haghighi-Mood have both resigned from the medical device company.
Endologix posts Q3 sales surge but losses widen
Endologix (NSDQ:ELGX) posted sales growth of nearly 25% during the 3rd quarter, but losses widened by nearly 58%.
Irvine, Calif.-based Endologix posted losses of $9.5 million, or 14¢ per share, on sales of $33.3 million for the 3 months ended Sept. 30. That’s a profit slide of 57.9% on sales growth of 24.6% compared with the same period last year.
Endologix shares gain 5 points in days following Q2 report
Iguana Healthcare Partners raises $54M investment fund | Wall Street Beat
New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests.
The funding, raised among 20 unnamed investors, will support Iguana’s interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.
MassDevice.com +3 | The top 3 med-tech stories for June 19, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Recalls: FDA makes Endologix catheter introducer recall Class I
BlackRock boosts medical device stakes
BlackRock Inc., 1 of the world’s largest hedge funds, boosted its stake in a clutch of medical device companies, with 1 exception.
Edwards CEO Mussallem details U.S. Sapien sales guidance, updates on CoreValve case | Wall Street Beat
Edwards Lifesciences (NYSE:EW) chairman & CEO Michael Mussallem said the medical device company expects to post U.S. sales of $390 million-$440 million for its flagship Sapien heart valve, adding 200 new sites over the next 2 years to its existing roster of 200 sites.
Endologix narrows losses amid strong sales growth in Q3
Endologix (NSDQ:ELGX) made progress in its 3rd quarter, narrowing losses despite a $5 million lawsuit loss to Cook Medical.